PLEASE READ

IMPORTANT MEDICINE SAFETY INFORMATION

APPROVED BY THE

HPRA
An tÚdarás Rialála Táirgí Sláinte
Health Products Regulatory Authority

Roche Products (Ireland) Limited
3030 Lake Drive
Citywest Business Campus
Dublin 24
D24 KX6Y
Ireland

13-Feb-2026

Annual Vaccination Reminder for Piasky▼ (crovalimab)

Dear Healthcare Professional,

We are sending you this annual vaccination reminder because you are involved in the prescribing or dispensing of Piasky (crovalimab).

Please remember that all patients who are receiving crovalimab treatment must be vaccinated against meningococcal infections caused by *Neisseria meningitidis* serogroups A, C, W, Y, and B where available locally. Please assess your patients' vaccine history for meningococcal infections and ensure all are up to date according to current local guidelines for vaccination use. During treatment, patients may require additional doses of vaccines in order to remain up to date with the recommended vaccinations. Please ensure the patient receives these vaccinations.

These steps are important to mitigate the risk of meningococcal infection for your patients who are receiving treatment with crovalimab.

Further information

For further information about this product, please contact Medical Information at Roche Products (Ireland) Limited by telephone (01 4690700) or email (Ireland.druginfo@roche.com).

For a copy of the current Summary of Product Characteristics or further information regarding vaccinations, please refer to the crovalimab Summary of Product Characteristics available on www.hpra.ie and www.medicines.ie.

IE Version 2.0.3
M-IE-00001991
Date of preparation: April 2026
Date of HPRA approval: April 2026

Call for reporting

Reporting of suspected adverse events or reactions

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions (see details below). Reporting suspected adverse events or reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Where possible, healthcare professionals should report adverse events or reactions by brand name and batch number.

In the event of a suspected adverse event, please report it to:
The Drug Surveillance Centre,
Roche Products (Ireland) Limited,
3030 Lake Drive, Citywest Business Campus,
Dublin 24, D24 KX6Y, Ireland
Telephone: (01) 4690700
Email: ireland.drug_surveillance_centre@roche.com

Alternatively, suspected adverse reactions should be reported to:
HPRA Pharmacovigilance
Website: www.hpra.ie

Yours sincerely,

_____

Abdul Al Khateeb
Country Medical Director

Data Protection Statement
Roche Products (Ireland) Limited ("Roche") process your personal data as part of sending this communication to you. More generally, Roche may hold and use personal data provided by you and disclose it to other companies in the Roche group, to partners, agents and service providers of Roche and governmental agencies and bodies for the purposes of complying with Roche's legal obligations and for the purposes of our legitimate interests in conducting our business in a responsible and commercially prudent manner. Your personal data may be transferred outside of the European Economic Area, but any transfers shall be made in accordance with data protection law. You have various rights under data protection law, including the rights to access your personal data and to have any inaccuracies in such data corrected or deleted. Please see our privacy notice on www.roche.ie for further details.

Roche Products (Ireland) Limited
3030 Lake Drive, Citywest Business Campus, Dublin 24, D24 KX6Y, Ireland (Registered Office)

Registered in Ireland No. 214337

Directors: A. Muir (British), E. Hassan (Egyptian), J. Cortizo (Swiss), A. Mac Cann, S Davis (Co-Sec UK)

IE Version 2.0.3
Date of HPRA approval: April 2026